Why the study?
Does indexing LVEDV to VO2peak improve the differentiation of physiological vs. pathological left ventricular dilatation compared to BSA?
Does indexing LVEDV to VO2peak improve the differentiation of physiological vs. pathological left ventricular dilatation compared to BSA?
Answers are grounded in this paper and cite their sources.
Indexing left ventricular end-diastolic volume to peak oxygen uptake is a promising approach to differentiate physiological athletic remodeling from pathological dilatation, though it requires validation in larger cohorts.
This editorial refers to ‘Indexing cardiac volumes for peak oxygen uptake to improve differentiation of physiological and pathological remodeling: from elite athletes to heart failure patients’, by J.M. Letnes et al., https://doi.org/10.1093/ehjci/jead034. Cardiac chamber quantification is part of routine evaluation in every cardiac patient. In order to define normal ranges and compare values in individuals with varying body sizes, sex-specific indexing to body surface area (BSA) is recommended.1 However, data have been published suggesting that different anthropomorphic measurements, such as fat-free mass (FFM), might more accurately define normal ranges.2 Furthermore, cardiac chamber size is dependent not only on body size and sex but also on metabolic demand. Accordingly, elite athletes can present with left ventricular dilatation as a physiological adaptation.3 Specifically, male athletes engaged in endurance sport (e.g. cycling, long-distance running, or X-country skiing) show the highest degree of left ventricular cavity enlargement, which can be well explained by the high increase in cardiac output during exercise.3 Individuals with heart failure, be it due to dilated cardiomyopathy, ischaemia, or other causes, can also present with a dilated left ventricle. Since both individuals can present with the same changes in chamber volumes, difficulty arises in differentiating the physiological adaptations from pathological changes, as indexing to BSA does not aid in differentiating these groups. Hence, findings of a dilated left ventricle in an athlete remain a frequent clinical conundrum. The reason why this difference has great clinical relevance is that intense competitive sports may increase the risk of adverse cardiac events in individuals with structural cardiac diseases. Sport-related sudden cardiac death in athletes is an extremely rare event, but it may occasionally occur in individuals with dilated cardiomyopathy; in a study from the US population, dilated cardiomyopathy accounted for 1% of sudden death in athletes, whereas in a prospective study from the UK, one out of eight sudden cardiac deaths in a large prospective cohort of football athletes followed up for almost 7 years was due to dilated cardiomyopathy (12.5%).4,5 Therefore, when a diagnosis of dilated cardiomyopathy has been established, current guidelines recommend personalized sport prescription and, in some cases, also competitive sport restriction.6 However, the differential diagnosis is not straightforward, and several studies have focused on possible features that can differentiate between physiological and pathological dilatation with the use of cardiac imaging modalities.7–10 Letnes et al.11 present data on indexing left-sided chamber volumes using peak oxygen uptake (VO2peak) to improve the classification of physiological and pathological dilatation. To define normal ranges, the authors compared data from 1190 participants of the Trøndelag Health Study with data on cardiopulmonary exercise testing (CPET; HUNT4 Fitness Study), which represented a healthy sample of the general population. Athletes were explicitly excluded from this dataset. The authors found a stronger correlation between left ventricular end-diastolic volume (LVEDV) and VO2peak (explaining 52% of variance in a univariate regression model) than with FFM or BSA (explaining 44 and 32% of variance, respectively). It is also noteworthy that oxygen pulse (O2 pulse), defined as VO2peak divided by heart rate (VO2peak/HR), explained 53% of the variance. This in itself is not a novel finding, and this work is in line with previous studies as also reported by the authors.11 However, in a next step, the authors defined normal ranges for LVEDV/VO2peak with cut-off values of >57 mL/L in women and >54 mL/L in men. These values were then applied to a cohort of 71 athletes (elite athletes n = 13) and 61 heart failure patients (HFrEF n = 44, HFmrEF n = 12, HFpEF n = 5). When indexing LVEDV to VO2peak instead of BSA, the percentage correctly classified that the rate of heart failure patients increased from 39 to 95% and the percentage of athletes who were incorrectly classified decreased from 25 to 1. Thereby, the authors are the first to leverage this ratio to successfully differentiate between pathological changes in heart failure and physiological adaptations to increased metabolic demand in athletes using normal ranges of LVEDV indexed by VO2peak. Using a volumetric and functional measurement as a quotient is an interesting concept. While the authors use a large sample size (n = 1190) to define normal ranges, the sample size used to test the discriminatory ability pale in comparison (71 athletes and 61 heart failure patients). Correct classification needs to be robustly shown in larger sample sizes, ideally also including individuals with dilated cardiomyopathy in the same age range as the athletes. A very important aspect to keep in mind is that individuals with subclinical dilated cardiomyopathy are sometimes capable of excellent physical performance, and in these cases, the information derived from cardiopulmonary testing may be less useful in differentiating pathology from physiology. A study by Millar et al.9 showed that the largest proportion of a group of adult asymptomatic patients with non-ischaemic dilated cardiomyopathy (71%) had a normal peak VO2 with some (20%) achieving >120% of predicted. Therefore, in the setting of young trained individuals with mild or subclinical form of dilated cardiomyopathy, the data-derived CPET may be completely normal, and it is possible that the ratio between LVEDV and peak VO2 may not be able to discriminate between the two conditions with high sensitivity and specificity. These individuals with subclinical and underdiagnosed cardiomyopathies are nevertheless exposed to the risk of sudden cardiac death. Malhotra et al.5 reported that a soccer player with dilated cardiomyopathy died suddenly almost 8 years after a negative cardiac screening; this underscores the concept that (i) athletes with subclinical cardiomyopathies are sometimes able to compete at a very high level; and (ii) that the cardiac phenotype may manifest several years after cardiac screening and may only be detected if regular screening is performed. Moreover, since O2 pulse has a slightly better explanatory capacity compared with VO2peak, it is curious that in the study by Letnes et al.,11 O2 pulse has a lower discriminatory capacity with 78 vs. 95% of correctly classified heart failure patients and 13 vs. 1% incorrectly classified athletes. VO2 is directly measured in CPET and defined as stroke volume (SV) × HR × arteriovenous blood oxygen content difference [C(a-v)O2]. O2 pulse is then calculated by dividing VO2 by HR, defining it as SV × C(a-v)O2. Assuming a constant C(a-v)O2, O2 pulse can be considered a surrogate marker for SV.12 Keeping with our understanding of cardiac physiology, we would expect O2 pulse as surrogate marker for SV to have a better discriminatory ability between athletes who have a large SV and heart failure patients with a low SV. Since the only difference between VO2 and O2 pulse is HR, therein must lie the explanation. The maximum HR was 174, 188, and 124 beats/min for the reference population, athletes, and heart failure patients, respectively. While data on medication are not available, it is possible that the majority of heart failure patients were on beta-blockers. Interestingly, beta-blockers do not affect exercise capacity (VO2peak) as the blunted HR response is compensated by increased SV and/or oxygen extraction (O2 pulse).13 As VO2peak remains unchanged in heart failure patients taking beta-blockers, O2 pulse increases proportionally to the decrease in HR. It must therefore be the combination of reduced SV and blunted HR response by beta-blockers which at least partially explain why O2 pulse is a worse discriminator between athletes and heart failure patients in this cohort and why VO2peak is more robust. It would be interesting to evaluate the discriminatory ability of this ratio in a heart failure population who are not on beta-blockers such as patients with HFpEF. In our opinion, based on this study, the use of combined echocardiography and CPET data could be used as an additional piece of a more complex and integrative evaluation of the athlete that include clinical data, resting and exercise electrocardiogram, as well as multimodality imaging.14 However, since the CPET is not part of the routine examination of the athletes, we recommend this examination only to be performed in athletes with a high suspicion for dilated cardiomyopathy. In the following Figure 1, we report our proposed algorithm for athletes with large cavity size. A large cavity size is traditionally defined as a left ventricular end-diastolic diameter >63 mm in male (or >35 mm/m2) and >56 mm (or 40 mm/m2) in female athletes.3,15 In terms of left ventricular volumes a 3D echocardiography study reported values up to 268 mL (136 mL/m2) in male endurance athletes and 215 mL (107 mL/m2) in female athletes engaged in combined endurance and strength disciplines.16 In a meta-analysis of cardiac magnetic resonance (CMR) studies the upper limits of LVEDV were 220mL and 121 mL/m2 in endurance athletes.17 Criteria for differential diagnosis between physiological and pathological LV hypertrophy in athletes. SCD, sudden cardiac death; ECG, electrocardiogram; LV, left ventricle; RV, right ventricle; EF, ejection fraction; LVEDV, left ventricular end-diastolic volume; ECV, extracellular volume; CPET, cardiopulmonary exercise test; CMR, cardiac magnetic resonance. In the majority of cases, a routine protocol is sufficient to differentiate pathologic vs. physiologic hypertrophy; however, when the diagnosis has not been resolved, a second-level evaluation including blood test, CPET, and CMR may be suggested.7–11,18,19 In our opinion, the ratio LVEDV/VO2max is a fascinating concept worth following up on. We believe it is important to remember that sports cardiology and exercise parameters apply not only to elite athletes but also to every cardiac patient according to the current guidelines, as regular physical activity improves the quality of life and decreases mortality and morbidity.6 The concept developed by Letnes et al. combining volumetric and functional parameters can be expanded to a broad range of patients. We strongly believe that important prognostic information may be obtained in heart failure or valvular heart disease patients where objective measurements are needed to decide the optimal treatment strategy. This raises the question whether ratios such as LVEDP/VO2peak can more accurately discern between a compensated and a failing left ventricle, adding information to better patient selection for intervention and outcomes. In the future, we would like to see prospective longitudinal data on combined CPET and echocardiography to also better understand its prognostic significance. No new data were generated or analysed in support of this research.
No takes yet. Share an insight, caveat, or question.
Niederseer et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: